Development and Validation of an Ipsilateral Breast Tumor Recurrence Risk Estimation Tool Incorporating Real-World Data and Evidence From Meta-Analyses: A Retrospective Multicenter Cohort Study Data ...

Dit nieuw toegekende Amerikaanse patent is een aanvulling op bioAffinity’s groeiende wereldwijde patentportefeuille, die nu 18 toegekende en 33 aangevraagde patenten omvat in verschillende landen, ...

Baseline LDH as a prognostic biomarker of early treatment failure in lung cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text ...

Affinity Technologies, Inc. ( ($BIAF) ) has issued an update. On October 16, 2025, bioAffinity Technologies, Inc. announced it received a ...

BERLIN -- Adding a test that predicts cancer signal origin to single standard of care (SoC) screening substantially increased ...

Investing.com -- bioAffinity Technologies Inc (NASDAQ:BIAF) stock surged 14% on Thursday after the biotechnology company announced it received a notification of allowance from the United States Patent ...

An artificial intelligence (AI) deep learning tool that estimates the malignancy risk of lung nodules achieved high cancer detection rates while significantly reducing false-positive results. Results ...

Detailed price information for Bioaffinity Technologies WT (BIAFW-Q) from The Globe and Mail including charting and trades.

A study published in JCO Clinical Cancer Informatics demonstrates that machine learning models incorporating patient-reported outcomes and wearable sensor data can predict which patients with ...

SEVEN NEWS. LUNG CANCER REMAINS THE LEADING CAUSE OF CANCER RELATED DEATH IN THE UNITED STATES. AS MEDICAL EXPERT DOCTOR RAMO EXPLAINS, RECENT GUIDELINE CHANGES COULD HELP SAVE THOUSANDS OF LIVES.